Investing in Clivi: A Game-Changing Solution for Diabetes Management
In 2021, diabetes cast a long and dark shadow over Mexico, resulting in over 140,000 lives lost¹ and firmly establishing itself as the second deadliest disease in the country. It’s not just a health crisis; it’s an economic burden, costing the government and the 21 million people struggling with it an astonishing US$33 billion annually, a heavy out-of-pocket expense that averages US$1,597 per person².
However, looking beyond the numbers, diabetes in Mexico is a social issue with far-reaching consequences. It disproportionately affects the already disadvantaged sectors of society—the low-income communities and indigenous groups who often face daunting barriers to quality healthcare, adequate nutrition, and education.
For the past 15 years, we have kept a close eye on the health tech landscape in Latin America, seeking an investment opportunity that ticks all the right boxes: A) stellar leadership known for their execution prowess, B) a solution that’s proven to meet market demands, and C) the potential for a substantial, positive impact. In a serendipity of events, we found all of the above and more when we reconnected with Ricardo Moguel and his team at Clivi, a Mexican startup focused on diabetes management. They recently announced a US$10 million seed round, a round that we were proud to co-lead. Here’s why we couldn’t be more excited about our partnership with Clivi:
🚀 Experienced and Visionary Leadership: Leading Clivi is a team of visionary entrepreneurs who have successfully drawn top talent from relevant industries. CEO Ricardo Moguel brings invaluable experience from his time at Doctoralia, and COO Bruno Garza adds leadership experience from his roles at Doctoralia and major companies like General Motors and Paramount Pictures. CTO Kyle, with a track record at companies like Capital One and BMW, rounds out the founding team. This talented group has assembled a dedicated team of over 50 experienced individuals poised to make a substantial impact. We recognize the value of strong leadership in navigating the complexities of the healthcare industry and driving the company’s success.
🏥 Addressing a Pressing Healthcare Need: Diabetes is a rapidly growing health concern across Mexico and Latin America, especially for underserved communities. Clivi’s all–in-one approach to diabetes care and management has the potential to make an immense difference in the region. We’re fully aware of the urgency to tackle this healthcare crisis, and in Clivi, we have found a game-changing solution that aligns perfectly with our investment strategy.
🌟 Creating Positive Social Impact: At Dalus Capital, we are renowned for investing in companies that deliver both financial returns and positive social impact. Our investment in Clivi is a testament to our commitment to drive positive change in Latin America. Clivi’s mission to enhance diabetes care, improve quality of life, and reduce healthcare disparities aligns perfectly with our vision for a better future for everybody.
💡 Technology-Driven Innovation: Clivi’s standout feature is its innovative use of current technology to improve diabetes care. Through platforms like WhatsApp, which are already in use by the majority of the population, Clivi connects patients with a team of specialists, offering personalized guidance and support. We firmly believe in the transformative power of technology in healthcare, and investing in Clivi resonates with our commitment to backing innovative, tech-driven companies set to disrupt traditional healthcare models.
📊 Outstanding Medical Results: Since its launch in 2021, Clivi has achieved rapid growth, benefiting thousands of patients. A staggering 94% of their patients achieve diabetes control within six months—a testament to its effectiveness. The numbers speak for themselves: 9 out of 10 patients see improved blood glucose levels in the first 90 days, and 80% significantly reduce their risk of complications. This includes a remarkable 2.4-point drop in glycated hemoglobin, a crucial indicator linked to increased life expectancy and lower risks of heart diseases and other chronic conditions. Clivi is making a tangible, positive impact by providing better healthcare to thousands every month.
We’re beyond excited to embark on this transformative journey with Clivi. This marks our fifth investment from Fund 3 and perfectly aligns with our strategy of supporting outstanding teams leading high-growth startups with a profound impact through innovation. With Clivi, we look forward to advancing diabetes care in Latin America and paving the way for a healthier future for those affected by this disease. ❤️🩹